SEC Form 424B4 filed by Artiva Biotherapeutics Inc.
Unavailable
Unavailable
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/13/2024 | $21.00 | Buy | Jefferies |
8/13/2024 | $23.00 | Overweight | Cantor Fitzgerald |
8/13/2024 | Buy | TD Cowen | |
8/13/2024 | $18.00 | Outperform | Wedbush |
8/13/2024 | $23.00 | Buy | Needham |
Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and manufacturing expertise to advance AlloNK® in autoimmune diseases Initial data for AlloNK® in autoimmune indications expected H1 2025 Robust balance sheet with cash, cash equivalents and investments of $199.6 million as of September 30, 2024, is expected to fund operations at least through end of 2026 SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial
SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 3:30 p.m. GMT, in London, UK. Members of the Artiva management team will also be available to participate in in-person investor meetings with investors who are registered to attend the conference. Investors and the general public are invited to listen to a live webcast of the fir
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensive background in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. (NASDAQ:CDXS), a leading enzyme engineering company, and was the former CTO of Allog
SC 13G/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)
SC 13D/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)
SC 13G - Artiva Biotherapeutics, Inc. (0001817241) (Subject)
4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
3 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensive background in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. (NASDAQ:CDXS), a leading enzyme engineering company, and was the former CTO of Allog
Jefferies initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $21.00
Cantor Fitzgerald initiated coverage of Artiva Biotherapeutics with a rating of Overweight and set a new price target of $23.00
TD Cowen initiated coverage of Artiva Biotherapeutics with a rating of Buy
10-Q - Artiva Biotherapeutics, Inc. (0001817241) (Filer)
8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)
8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)
4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)